L'intérêt à découvert pour Silvergate Capital donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Silvergate Capital. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Silvergate Capital (OTC:SICLQ) Stock, Rapport sur les intérêts à découvert

Silvergate Capital Corp is a provider of various financial infrastructure solutions and services. Its solutions and service offerings include Silvergate Exchange Network, Cash Management Solutions and Deposit Account Services. Its customers include U.S. exchanges and global investors in the digital currency industry. The company also provides financial services that include commercial banking, business lending, commercial and residential real estate lending, and mortgage warehouse lending.

5.375% PRF PERPETUAL USD 25 - Ser A 1/40th Int

SILVERGATE CPTL D/S PFD A by Silvergate Capital Corporation

Silvergate Capital Corp

-- First ever clinical data supporting safety and efficacy of Prime Editing in humans --
-- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative --
-- Rapid engraftment observed in both neutrophils and platelets --
-- Encouraging safety profile; no serious adverse events related to PM359 --
-- Initiating efforts to explore continued clinical development opportunities for PM359 external to Prime Medicine --
CAMBRIDGE, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced positive initial data from the first patient dosed in its ongoing Phase 1/2 clinical study of PM359 in Chronic Granulomatous Disease (CGD). Preliminary results from the first patient demonstrated that PM359 was well-tolerated, showed rapid engraftment and restored NADPH oxidase activity to well above the threshold for clinical benefit, as measured by the dihydrorhodamine (DHR) assay.
CGD is a rare inherited disease that leads to recurrent, debilitating and often life-threatening infections. It is caused by mutations in genes, including&nbsp;NCF1, that encode proteins that form the NADPH oxidase complex, an enzyme that kills bacteria and fungi to control infection. PM359, an ex vivo Prime Edited autologous hematopoietic stem cell (HSC) product for the treatment of p47phox CGD and the first Prime Editor generated therapy to be administered in humans, is designed to correct the delGT mutation in NCF1, the most prevalent disease-causing mutation in the p47phox variant of CGD, thereby addressing its underlying pathophysiology. Prime Medicine estimates that CGD causative mutations occur in between one in 100,000 and one in 200,000 births in the United States, with approximately 25 percent of patients presenting with the p47phox form of the disease.

Biotech

News

General

PRME

Prime Medicine Announces Initial Data From First Patient Dosed In Phase 1/2 Trial Finds Single Dose Of PM359 Led To 58% 'DHR Positivity' By Day 15 And 66% By Day 30, Well Above Levels Believed To Be Potentially Curative

Hong Kong leading logistics solutions provider New Century Logistics (BVI) Limited (hereinafter referred to as "New Century") today announced the formal signing of a Memorandum of Understanding ("MOU") with Silk Way Airlines Limited (hereinafter referred to as "Silkway"), a well-known air cargo airline in Hong Kong. Both parties will explore innovative solutions in the international air freight logistics sector based on resource sharing and complementary strengths, aiming to enhance global supply chain efficiency for their clients.
Stronger collaboration
According to the MOU, New Century and Silkway will conduct in-depth cooperation in the following directions:
<ul>
<li>Joint development of international air freight logistics solutions: integrating New Century's global logistics network with Silkway's air cargo resources to provide end-to-end efficient transportation services for cross-border trading enterprises.</li>
<li>Market intelligence and logistics best practices sharing: optimize route planning, cost control and risk management capabilities through data exchange and experience sharing.</li>
<li>Collaborative marketing and brand promotion: Joint promotion of services offered by both parties to expand business coverage in Asia Pacific, Europe and emerging markets.</li>
<li>Customer experience upgrade: build a seamless logistics service system, improve the transparency of cargo tracking and delivery timeliness.</li>
</ul>

NCEW

New Century Logistics Signs MOU With Silk Way Airlines To Explore Innovative Solutions In International Air Freight Logistics Sector

Wells Fargo analyst Praneeth Satish maintains Nextracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) with a Overweight and raises the price target from $69 to $71.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Nextracker, Raises Price Target to $71

FRSX

Trading Halt: Halt status updated at 8:35:00 AM ET: Quotation Resumption: News and Resumption Times

Evercore ISI Group analyst David Raso maintains Cummins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) with a Outperform and lowers the price target from $451 to $419.

Evercore ISI Group Maintains Outperform on Cummins, Lowers Price Target to $419

-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology --
-- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 --
-- Allan Reine, M.D., CFO, to succeed Keith Gottesdiener, M.D., as CEO; Jeff Marrazzo, member of the Board of Directors, named Executive Chair --
-- Implementing cost cutting measures to significantly reduce cash needs in advance of key data inflection points --
CAMBRIDGE, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced a strategic restructuring, including the deprioritization of its Chronic Granulomatous Disease (CGD) programs, as well as a cost and workforce reduction to focus on its liver franchise and programs funded through external partnerships.
Prime Medicine is currently advancing in vivo programs to cure two of the largest genetic liver diseases, Wilson's Disease and Alpha-1 Antitrypsin Deficiency (AATD), with initial clinical data from both programs expected in 2027. Prime Medicine will also continue its in vivo Cystic Fibrosis program with support from the Cystic Fibrosis Foundation, and its efforts to develop Prime Edited CAR-T products for hematology, immunology and oncology in partnership with Bristol Myers Squibb. In addition, Prime Medicine will continue to pursue additional business development opportunities to accelerate innovation, ensure the broadest application of Prime Editing, and further bolster its financial resources.
Also today, Prime Medicine announced that Keith Gottesdiener, M.D., has decided to step down as Chief Executive Officer (CEO) and a member of the Company's Board of Directors, effective immediately. Allan Reine, M.D., Prime Medicine's Chief Financial Officer (CFO), has been named CEO and member of the Board of Directors and Jeff Marrazzo, member of the Company's Board of Directors, has been named Executive Chair.

Management

Prime Medicine Implementing Cost Cutting Measures To Significantly Reduce Cash Needs In Advance Of Key Data Inflection Points; Allan Reine, CFO, To Succeed Keith Gottesdiener, As CEO; Jeff Marrazzo, Member Of The Board Of Directors, Named Executive Chair

Patrick Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PATK#NASDAQ">PATK</a>) ("Patrick" or the "Company"), a leading component solutions provider for the Outdoor Enthusiast and Housing markets, announced that Jake Petkovich will rejoin Patrick as President – Marine, succeeding Rick Reyenger, effective May 19, 2025. Mr. Reyenger will remain with the Company and move to a strategic advisory role to support continuity and ensure a smooth and seamless transition across the Company's Marine businesses.

PATK

Patrick Industries Says Jake Petkovich To Rejoin As President – Marine, Succeeding Rick Reyenger, Effective May 19, 2025

Niu Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIU#NASDAQ">NIU</a>) sees Q2 sales of $181.487 million-$194.441 million.

Guidance

Niu Tech expects Q2 2025 Revenue between RMB 1.317B and RMB 1.411B, YoY increase of 40% to 50%.

The renewal from a key client demonstrates strong loyalty, while a new major deal reflects continued growth momentum heading into FY2026.
BEIJING, May 19, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTSS#NASDAQ">DTSS</a>) ("Datasea" or the "Company"), a Nevada-based technology company specializing in acoustic high-tech products and 5G+AI multimodal digital solutions, today announced that its subsidiaries have signed two new service contracts totaling up to $100 million for the provision of 5G-AI multimodal digital services over a 12-month period. The customers include long-term partner Qingdao Ruizhi Yixing Information Technology Co., Ltd. ("Qingdao Ruizhi Yixing") and a new key client, Qingdao Dong'an Information Technology Co., Ltd.
Under the terms of the agreements, Datasea will deliver customized 5G-AI digital services, including data Top-up solutions and AI-powered communication tools, to both Qingdao Ruizhi Yixing and Qingdao Dong'an. Each contract is valued up to $50 million, representing a strong vote of recognition and confidence in the performance and value of Datasea's 5G-AI solutions.

DTSS

Datasea Subsidiaries Sign Two New Service Contracts Totalling Up To $100M For Provision Of 5G-AI Multimodal Digital Services Over 12-Month Period

TransDigm Group and Servotronics Announce ~$110M Definitive Merger Agreement For Servotronics To Become Wholly Owned Subsidiary Of TransDigm

Evercore ISI Group analyst David Raso maintains Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) with a In-Line and lowers the price target from $375 to $373.

Evercore ISI Group Maintains In-Line on Caterpillar, Lowers Price Target to $373

Evercore ISI Group analyst Michael Binetti maintains Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) with a Outperform and raises the price target from $65 to $70.

BIRK

Evercore ISI Group Maintains Outperform on Birkenstock Holding, Raises Price Target to $70

VNRX

VolitionRx Publishes  "Evaluation of plasma nucleosome concentrations and the effect of pre-analytical variables in healthy cats" In BMC Veterinary Research

Wells Fargo analyst Zachary Fadem maintains Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) with a Equal-Weight and lowers the price target from $85 to $75.

Wells Fargo Maintains Equal-Weight on Best Buy Co, Lowers Price Target to $75

Market-Moving Exclusives

Exclusives

GTBP

EXCLUSIVE: GT Biopharma Tells Benzinga 'The company plans on releasing more detailed results from Phase 1 later in 2025 following completion of additional dose cohorts'

EXCLUSIVE: GT Biopharma Tells Benzinga 'Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2'

GT Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) announced Monday that it has successfully completed dosing in Cohort 1 and started dosing in Cohort 2 of its Phase 1 dose escalation trial for GTB-3650. The therapy is a second-generation TriKE therapeutic targeting relapsed or refractory CD33-expressing hematologic malignancies.
GT Biopharma specializes in immuno-oncology therapies using its proprietary TriKE NK cell engager platform and holds an exclusive global license with the University of Minnesota for its development and commercialization.
No safety or tolerability issues were observed in Cohort 1, allowing progression to the next cohort, the company said.
Early biomarker analysis from Cohort 1 patients indicates increased immunologic activity, suggesting activation and expansion of natural killer (NK) cells.
The trial, which may include up to 14 patients across seven cohorts, involves two-week dosing blocks over a four-month period and will evaluate safety, pharmacokinetics, pharmacodynamics, NK cell expansion, and clinical activity.
The company said that it will release detailed results in 2025.
In January, the company had initiated patient dosing with GTB-3650 in the Phase 1 trial to evaluate the potential in patients with hematological malignancies.
Price Action: GTBP stock traded higher by 0.90% to $2.26 premarket at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/econ-s/25/05/45479078/moodys-downgrades-us-credit-rating-over-debt-deficit-concerns" target="_blank" rel="noreferrer noopener">Moody's Downgrades U.S. Credit Rating Over Debt, Deficit Concerns</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Health Care

EXCLUSIVE: GT Biopharma Advances Relapsed Blood Cancer Therapy Trial To Cohort 2 After Promising Early Safety Results

EXCLUSIVE: GT Biopharma Tells Benzinga Co. Advances GTB-3650 Phase I Trial To Cohort 2 Following Successful Initial Human Dosing And Evidence Of Early Immune Activation Signals

UHGWW

Trading Halt: Halt status updated at 8:30:00 AM ET: Quotation Resumption: News and Resumption Times

Wells Fargo analyst Zachary Fadem maintains AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) with a Overweight and raises the price target from $3850 to $4200.

Comments

Silvergate Capital

Intérêt court

Silvergate Capital (OTC:SICLQ) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL